- Home
- IBTA vs SUPN Comparison
IBTA vs SUPN Comparison
Compare IBTA & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- SUPN
- Stock Information
- Founded
- IBTA 2011
- SUPN 2005
- Country
- IBTA United States
- SUPN United States
- Employees
- IBTA N/A
- SUPN N/A
- Industry
- IBTA
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- IBTA
- SUPN Health Care
- Exchange
- IBTA Nasdaq
- SUPN Nasdaq
- Market Cap
- IBTA 2.2B
- SUPN 2.1B
- IPO Year
- IBTA 2024
- SUPN 2012
- Fundamental
- Price
- IBTA $65.34
- SUPN $33.05
- Analyst Decision
- IBTA Strong Buy
- SUPN Hold
- Analyst Count
- IBTA 10
- SUPN 2
- Target Price
- IBTA $89.20
- SUPN $36.00
- AVG Volume (30 Days)
- IBTA 178.9K
- SUPN 495.6K
- Earning Date
- IBTA 02-26-2025
- SUPN 02-25-2025
- Dividend Yield
- IBTA N/A
- SUPN N/A
- EPS Growth
- IBTA N/A
- SUPN 130.79
- EPS
- IBTA 0.48
- SUPN 1.07
- Revenue
- IBTA $368,548,000.00
- SUPN $651,972,000.00
- Revenue This Year
- IBTA $18.72
- SUPN $7.94
- Revenue Next Year
- IBTA $16.57
- SUPN N/A
- P/E Ratio
- IBTA $134.54
- SUPN $30.90
- Revenue Growth
- IBTA 74.91
- SUPN 6.79
- 52 Week Low
- IBTA $41.87
- SUPN $25.53
- 52 Week High
- IBTA $110.95
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- IBTA N/A
- SUPN 32.98
- Support Level
- IBTA N/A
- SUPN $32.53
- Resistance Level
- IBTA N/A
- SUPN $39.99
- Average True Range (ATR)
- IBTA 0.00
- SUPN 1.31
- MACD
- IBTA 0.00
- SUPN -0.69
- Stochastic Oscillator
- IBTA 0.00
- SUPN 6.71
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.